<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Antimicrobial Resistance</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written e</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">vidence </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">submitted by</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> the Society for Applied Microbiology </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">(AMR0036)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Society for Applied Microbiology</span><span style="font-family:'Times New Roman'; font-size:11pt"> (S</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">f</span><span style="font-family:'Times New Roman'; font-size:11pt">AM)</span><span style="font-family:'Times New Roman'; font-size:11pt"> is the oldest microbiology society in the UK. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">S</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">f</span><span style="font-family:'Times New Roman'; font-size:11pt">AM envisages a future where applied microbiology research and development is strong in the UK and beyond, and the applications of microbiology contribute significantly to all global challenges facing humanity, including infectious diseases; the changing environment; sustainability of energy, food, water, and land resources; and economic growth.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">This response is in addition to S</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">f</span><span style="font-family:'Times New Roman'; font-size:11pt">AM’s endorsement of the Society of Biology submission. S</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">f</span><span style="font-family:'Times New Roman'; font-size:11pt">AM is a member organization of the Society of Biology.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q. How has antimicrobial resistance developed in the past decade?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Widespread emergence of resistance to third-generation cephalosporins in both pathogens and non-pathogens, resulting in community outbreaks of </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Escherichia coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> exhibiting resistance to such antibiotics, with numerous fatalities.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Increasing incidence of commensal </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> with such resistance in poultry in several European countries, resulting in the spread of cephalosporin-encoding resistance genes to pathogens, with fatal consequences in some cases.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Emergence of resistance to carbapenem antibiotics in already multiple drug-resistant pathogenic bacteria, predominantly in countries in the Indian sub-continent, thus making infections with such strains almost untreatable. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Worldwide spread of such strains as a result of international travel, resulting in untreatable infections in developed countries such as those in Europe and North America.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Recent appearance of resistance to carbapenem antibiotics in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Acinetobacte</span><span style="font-family:'Times New Roman'; font-size:11pt">r spp, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Salmonella</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">enterica</span><span style="font-family:'Times New Roman'; font-size:11pt"> and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">E. coli</span><span style="font-family:'Times New Roman'; font-size:11pt"> in food animals in some European countries.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 29.41pt; padding-left:6.59pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Emergence of extensively drug resistant tuberculosis (XDR-TB).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Detection of MRSA strains with varying levels of resistance to vancomycin (from vancomycin intermediate to vancomycin resistant).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Increase in essentially untreatable gonorrhoea.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q.</span><span style="font-family:Calibri; font-size:11pt; font-variant:small-caps">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is a severe lack of understanding of exchange of genes in the wider environment and what drives this.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">It will also be important to understand what resistance reservoir exists in normal human and animal commensal microbiota (even prior to any antibiotic exposure). </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">We need to know:</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">What is the composition of resistance genes and/or resistant organisms in gut, skin, oral cavity etc. and how does this contribute to the emergence of resistant pathogens? How does antibiotic exposure alter this in the short and long term? </span></li><ul type="circle" style="margin:0pt; padding-left:0pt"><li style="font-family:'Courier New'; font-size:11pt; margin:0pt 0pt 0pt 83.6pt; padding-left:6.4pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This could tell us the distribution of resistance genes, particularly those encoding resistance to critically-important antibiotics (CIAs), or antibiotics of last resort, in human and food animal ecosystems in non-pathogenic and pathogenic bacteria.</span></li></ul></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Extent of transmission of resistance genes from bacteria from humans (both pathogens and non-pathogens) to animals, and particularly animals bred for food.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Extent of transmission of resistance genes from bacteria from animals, particularly food production animals, to bacteria in humans.</span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Contribution of foods imported into the country to the spread of resistant bacteria to humans.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Effects of ‘off-label’ use of antibiotics in both human and veterinary medicine in the development and spread of resistance.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Can the burden of resistance be reduced by removing the selective pressure (e.g. by reducing prescription of antibiotics or reducing use in animal foods)? This would require a large scale carefully controlled study.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The potential for metal resistance, particularly silver, as used in wound dressings.</span></li><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Resistance in clinical isolates is seldom seen but exposure around silver mines and in other non-clinical settings is documented to confer resistance. We know that a number of metal resistances are co-transmitted with antibiotic resistances on plasmids/transposons (genetic material) so the use of silver as an antimicrobial treatment in many different environments has the potential to start to select for resistant strains and could indirectly drive antibiotic resistance – this requires further investigation.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Silver is synergistic with a number of antibiotics and therefore has the potential to be extremely useful if we can understand how to use it appropriately.</span></li></ul></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q. Is there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the past, pharmaceutical companies have been prepared to invest to find formulations that are both effective antibiotics and also discourage/minimise the evolution of resistance. That isn’t the case at present and there is relatively little R&amp;D going on in this area. The reason appears to be the greater financial rewards available in developing other classes of drugs. This puts the onus on the UK government to fund antimicrobial drug development outside of the pharmaceutical companies and/or incentivise this work within the industry.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is also vital to first understand the drivers selecting for resistance, which may include as yet unknown factors. A quantitative risk assessment of the effects of different control measures in human and animal populations would provide the basis from which to develop new drugs that have the potential for greater longevity. There will always be a degree of selection pressure and as such bacteria remain ‘one step ahead’ but opportunities surely exist to minimise selection pressure and slow the development of resistance.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is a recent Journal of Antimicrobial Chemotherapy article that provides detailed analysis of the proportion of total infection research spend dedicated to research into antimicrobial resistance.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt">  The paper also outlines some recommendations for future direction of R&amp;D. In summary: despite the rapid emergence of antimicrobial resistance, the proportion of UK infection-research spend targeting this critical area remains small (3.9%; £102 million of £2.6 billion total spend). Mean annual funding ranged from £1.9 million in 1997 to £22.1 million in 2009. The study concluded that, whilst this is an encouraging indication of </span><span style="font-family:'Times New Roman'; font-size:11pt">increased emphasis and investment in this important area of research, the UK government must continue to fund antimicrobial resistance research in a sustained, targeted manner.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In October 2012 a conference entitled “Antimicrobial Resistance in Human and Veterinary Medicine – one medicine, one problem?” was held in the UK. The conclusions of the symposium, which was organised by the Royal College of Veterinary Surgeons, the Royal College of Pathologists, and the Royal College of Physicians in association with the Health Protection Agency and the Veterinary Medicines Directorate, were as follows:</span></li><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary and medical professionals must work together under the banner of ‘One Health, One Medicine’ to tackle antimicrobial resistance in a social context</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The</span><span style="font-family:'Times New Roman'; font-size:11pt"> issue of acquisition, evolution and transmission of AMR is complex and involves human and domestic animal populations (both food animal species and non-food companion animal species), but also wildlife and the environment. It is important to understand how these factors interact, particularly with increasing international movement of people, food and animals.</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In an increasingly connected world, it is evident that any measures need to tackle global use. The probability that selection for resistance will occur where antimicrobial usage is highest and least controlled, coupled with unprecedented mobility of humans, means that, whether AMR originates from animal use or human use, the threats in Britain and in Europe will often emanate from outside. </span></li></ul></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q. What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The continued promotion of responsible use of medicines in agriculture, as carried out by the responsible use of Medicines in Agriculture Alliance (RUMA) in the UK, the European Platform for the Responsible use of Medicines in </span><span style="font-family:'Times New Roman'; font-size:11pt">Agriculture</span><span style="font-family:'Times New Roman'; font-size:11pt"> (EPRUMA) and the OIE (World Organisation for Animal Health).</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In food animals, the withdrawal of antibiotics as growth promoters in the EU has been a highly effective measure in controlling the appearance and spread of some, mainly gram positive, organisms in food animals and thence their spread to humans through the food chain. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Similar controls for the prophylactic use of certain antibiotics in food production may have some effect, but such measures need to be balanced against possible effects on animal health and on food production. A typical example is weaner pigs where antibiotic treatment is seen as a crucial preventative measure. Parallel controls on the use of prophylactic use of antibiotics in humans should also be considered.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For food animals, EU-wide legislative controls to reduce the occurrence of pathogenic bacteria such as </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Salmonella </span><span style="font-family:'Times New Roman'; font-size:11pt">Enteritidis and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Salmonella </span><span style="font-family:'Times New Roman'; font-size:11pt">Typhimurium in poultry have been highly effective in reducing the occurrence such bacteria, including antibiotic-resistant strains of these serovars, as these bacteria are frequently resistant to commonly-used antibiotics as a consequence of antibiotic use in certain food production animals.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Of fundamental importance in controlling the occurrence and spread of antibiotic-resistant organisms is education. Many medical doctors prescribe antibiotics unnecessarily; veterinarians also often use antibiotics as a substitute for poor husbandry, thereby perpetuating the occurrence of antibiotic-resistant strains in the food chain.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 29.41pt; padding-left:6.59pt; text-align:justify; text-indent:0pt"><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">Many of the antibiotic resistant strains (gram positive and gram negative) are isolated from chronic wounds so careful management of these patients are important so they do not become a source of infection. Frequent debridement of the wound using non-invasive techniques (care </span><span style="background-color:#ffffff; font-family:'Times New Roman'; font-size:11pt">here because aerosols can be produced) then topical application of antiseptic dressings until bacterial numbers are reduced, is effective. The wound then slowly heals.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The prevention of infectious disease through appropriate hygiene and biosecurity, through the use of vaccines where available, and by appropriate nutrition and housing of animals, reduces the need for antibiotic use on farms. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">High hygiene standards during slaughter, processing and preparation of animal products (including dairy and eggs) is vital. This means education of food industry workers on compliance with legislation and enforcement where breaches have occurred is effective to reduce the spread of food borne pathogens. Food hygiene campaigns aimed at the general population are also effective to reduce the transmission of bacteria through the food chain.</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q. What global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are many global initiatives underway to combat antibiotic resistance at a global level, particularly in respect of resistance in food animals. Some initiatives are as follows:</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">UK 1970 - The solution - Swann recommendations:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Ban on use of penicillin and tetracyclines as growth promoters</span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Caution in use of chloramphenicol </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Prescription only use of therapeutic antibiotics in veterinary medicine </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Enhanced surveillance of resistance through food chain </span></li></ul><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">EU 2006. Ban of use of growth promoters in animal feeds </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">‘Regulation 1831/2003/EC on additives for use in animal nutrition’ </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">‘This regulation will strengthen the EU’s rules on the safety of animal feed and complete the EU ban on the use of antibiotics as growth promoters Both these objectives are of major importance to the EU’s food safety strategy and indeed to wider considerations of animal health’</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">David Byrne, EU Commissioner for Health and Consumer Protection, 2006 </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">UK Chief Medical Officer Reports 2009, 2011 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">‘</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">There should be a ban on the use of certain types of antibiotics (quinolones and cephalosporins) in animals, in order to protect their activity in humans’ </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Sir Liam Donaldson, CMO, 2009 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">‘</span><span style="font-family:'Times New Roman'; font-size:11pt">N</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ational approach to tackling antimicrobial resistance should be managed jointly between DH and Defra to ensure that a comprehensive integrated programme is developed’. </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Dame Sally Davies, CMO, 2013 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">European Food Safety Authority (EFSA), 2011 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Scientific Opinion on the public health risks of bacterial strains producing ESBLsand/or AmpC β-lactamases in food and food-producing animals </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">‘A highly effective control option would be to stop all uses of cephalosporins/systemically active 3rd/4th generation cephalosporins, or to restrict their use (use only to be allowed under specific circumstances)’. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">European Parliament October 2011 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">‘European Parliament calls upon the European Commission to make legislative proposals to phase out the prophylactic use of antibiotics in livestock farming in the EU’ </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">European Parliament, 27 October 2011 </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">SANCO strategy on Antimicrobial Resistance</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5-year strategy presented on European Antibiotic Awareness Day,18 November 2011 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Holistic approach: public health, food safety, consumer safety, environment, animal health and welfare as well as non-therapeutic use of antimicrobials </span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To develop new tools to fight microbial infections </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To promote practices known to reduce antimicrobial resistance </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To reduce practices that may contribute to increase of antimicrobial resistance </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To further elaborate phenomenon of antimicrobial resistance and its sources/causes/consequences </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To improve communication among those involved </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">To promote international cooperation in tackling AMR </span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">WHO Europe strategy on antibiotic resistance </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Seven action areas: </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1. Promote national coordination </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2. Strengthen surveillance </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3. Promote rational use of antibiotics, including surveillance of antibiotic consumption </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4. Improve infection control and stewardship of antibiotic use in health care settings </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5. Promote surveillance, prevention and control of antibiotic resistance in the food chain </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6. Promote research and innovation on new antibiotics </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7. Improve awareness on antibiotic use and risk of increasing resistance </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Fighting antibiotic resistance a priority for WHO/Europe European strategy under development </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2011 publication suggests actions for tackling antibiotic resistance from a food safety perspective </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Key messages for countries </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1. Improve overall coordination </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2. Improve regulatory framework </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">3. Reduce the need for and promote prudent use of antibiotics </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">4. Improve surveillance </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">5. Advocate and communicate </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">6. Build capacity and provide training </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">7. Address knowledge gaps and research needs </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">WHO/FAO/OIE achievements on AMR since 1997 </span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">International collaboration established </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Codex Alimentarius, FAO, OIE, WHO </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">15 plus expert meetings and consultations Roles </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Codex and OIE: normative work </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">FAO and OIE: practical guidance and capacity building </span></li><li style="font-family:Symbol; font-size:11pt; margin:0pt 0pt 0pt 64.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">WHO: raise public awareness, monitoring, leading the debate</span></li></ul><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Critically-Important Antimicrobials (CIAs) WHO, 2007, 2009, 2011 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">e.g. Quinolones / flouroquinolones 3rd / 4th generation cephalosporins Carbapenams </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Codex: </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold; text-decoration:underline">ad hoc </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Intergovernmental Task Force on AMR, 2007-2010</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Objectives </span></p><p style="margin:0pt 0pt 16.3pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1. To assess the risks to human health associated with the presence in food and feed of antimicrobial resistant organisms, antimicrobial resistant genes or residues of antimicrobials </span></p><p style="margin:0pt 0pt 16.3pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">2. To develop risk management advice based on that assessment to reduce such a risk </span></p><p style="margin:0pt 0pt 16.3pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Outcome: Guidelines for the Risk Analysis of Foodborne Antimicrobial Resistance </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Codex Alimentarius: Strategic Plan 2008-2013</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Develop guidance for safe and prudent non-human antimicrobial usage for containment of resistance </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Description: </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Develop guidance within the remit of Codex mandate for safe and prudent antimicrobial usage for containment of resistance in food production which focuses on public health, is based on sound science and follows risk analysis principles, and takes into account the work of other international organizations. </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Timeline: </span><span style="font-family:'Times New Roman'; font-size:11pt">Completion by 2011 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Responsible parties: </span><span style="font-family:'Times New Roman'; font-size:11pt">Existing relevant Codex Committees, </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">ad hoc </span><span style="font-family:'Times New Roman'; font-size:11pt">Intergovernmental Task Force on Antimicrobial Resistance Codex Alimentarius: Strategic Plan 2008-2013 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">OIE List of Antimicrobials of Veterinary Importance</span><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Defines: </span></p><p style="margin:0pt 0pt 3.65pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Critically Important Antimicrobials </span></p><p style="margin:0pt 0pt 3.65pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Highly Important Antimicrobials </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Veterinary Important Antimicrobials</span><span style="font-family:'Times New Roman'; font-size:11pt">: </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">‘Critically Important’ include: </span></p><p style="margin:0pt 0pt 3.7pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Aminoglycosides </span></p><p style="margin:0pt 0pt 3.7pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Cephalosporins </span></p><p style="margin:0pt 0pt 3.7pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Macrolodes </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt">Quinolones/ fluoroquinolones </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Guidance on pre-approval information for registration of new veterinary medicinal products for food-producing animals with respect to antimicrobial resistance</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Harmonized technical guidance in E.U., Japan and the U.S. for registration of antimicrobial veterinary medicinal products intended for use in food-producing animals ,with regard to characterization of potential for a given antimicrobial agent to select for resistant bacteria of human health concern. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Information on: </span></p><p style="margin:0pt 0pt 3.2pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•Antimicrobial class </span></p><p style="margin:0pt 0pt 3.2pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•Mechanism and type of antimicrobial action </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•Antimicrobial spectrum activity -MICs </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">European Medicines Agency Press release, 16th April 2013 </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">‘Use of antibiotics in animals - European Medicines Agency to give advice to European Commission on public- and animal-health impact’ </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 4.8pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">‘One health’ perspective </span></p><p style="margin:0pt 0pt 4.8pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Multidisciplinary working group </span></p><p style="margin:0pt 0pt 4.8pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Scientific basis to inform decisions </span></p><p style="margin:0pt 0pt 4.8pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">First report, June 2013 </span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Final report, June 2014 </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">October 2011 ‘European Parliament calls upon the European Commission to make legislative proposals to phase out the prophylactic use of antibiotics in livestock farming in the EU’ </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">European Parliament, 27 October 2011 </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">UK, January 2011: Similar proposal made during House of Commons debate on antibiotic use on intensive farms</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">House of Commons, 9 January 2013</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">RUMA </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Press statement 26 March 2013 </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Preventive treatment (sometimes referred to as Prophylaxis) </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">‘Treatment with antibiotics of an animal or a group of animals, before clinical signs of infectious disease, in order to prevent the occurrence of disease or infection’. </span></p><p style="margin:0pt 0pt 3.7pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Must only be applied to animals diagnosed at high risk of bacterial disease, </span></p><p style="margin:0pt 0pt 3.7pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Must only occur under prescription by veterinarian on basis of epidemiological and clinical knowledge, </span></p><p style="margin:0pt 0pt 3.7pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Must not be applied systematically or routinely, </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">•</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Must not be used to compensate for poor hygiene or for inadequate husbandry conditions, or where improvements in animal husbandry could reduce need for antibiotic treatment. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold; text-decoration:underline">Food industry perspective</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The British Poultry Council have introduced a voluntary ban on the use of fluoroquinolones and 3rd and 4th generation cephalosporins in poultry production from January 2012. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Of note is that the European Medicines Agency (EMA), the European Centre for Disease Prevention and Control (ECDC), and the European Food Safety Authority (EFSA) have all realised the importance afforded to the control of infections caused by antibiotic-resistant bacteria, and many collaborative actions are underway. More pro-active collaborations between appropriate UK agencies and these bodies would be both welcome and desirable.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 30.63pt; padding-left:5.37pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Of paramount importance is controlling antibiotic usage in countries in the Far East. Antibiotics are used freely in these countries in both human and veterinary medicine, often with formulations that have not been subject to proper regulatory controls. This usage has undoubtedly contributed to the appearance of, and subsequent worldwide spread of organisms resistant to CIAs and last-resort antibiotics. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="a" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Environment pollution around factories producing antibiotics has been reported – see </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Environmental Toxicology and Chemistry</span><span style="font-family:'Times New Roman'; font-size:11pt">, Vol.28, No.12, pp. 2522-2527. Global regulation and compliance with respect to groundwater and drinking water is essential.</span><a name="_GoBack"></a></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q. What are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Strengths</span><span style="font-family:'Times New Roman'; font-size:11pt">:  realisation that there is a problem and that measure should be undertaken to combat this problem.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Department of Health 5 year strategy states at Point 2.1, page 8; ‘Increasing scientific evidence suggests that the clinical issues with antimicrobial resistance that we face in human medicine are primarily the result of antibiotic use in people, rather than antibiotics in animals’.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">Weaknesses</span><span style="font-family:'Times New Roman'; font-size:11pt">: lack of willingness to introduce comprehensive legislation to combat resistance development in both the human and veterinary sectors.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">October 2013</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Calibri; font-size:10pt">http://jac.oxfordjournals.org/content/early/2013/09/13/jac.dkt349.full.pdf+html</span></p></body></html>